Company profile
Maxion Therapeutics | Home
Maxion Therapeutics | We are using our revolutionary KnotBody technology to create first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AP01 | Transaction MzUyNzg5NjkzNGFkaXF6a2N4
Published 25 Jun 2026 08:48
Last confirmation statement made up date
AA | Transaction MzUxNDEyNjAxM2FkaXF6a2N4
Published 02 Apr 2026 14:27
Last accounts made up date
SH01 | Transaction MzQ0NDkwODI1M2FkaXF6a2N4
Published 26 Nov 2024 10:56
Company registered at Companies House
1 Apr 2023 to 31 Jan 2026
Autoimmune diseases such as Inflammatory Bowel Disease, Type 1 Diabetes, Rheumatoid Arthritis and Psoriasis are driven by the protective immune system attacking the body itself. These conditions are often poorly treated with existing therapeutics. Autoimmune diseases are driven by a subset of T cells (part of the body's immune system) which are uniquely d...
1 May 2021 to 31 Oct 2022
Maxion is a newly founded UK therapeutic development SME solving a significant unmet global need with its novel, disruptive platform that can generate antibody-like therapeutics to target ion channel-driven diseases. Taking inspiration from nature, Maxion's founders have combined ion channel modulating mini-proteins found in venom and other sources called...
